Perianal Crohn's disease and infliximab therapy

Surgeon

Volumn 2, Issue 5, 2004, Pages 258-263

  McNamara, Deborha A ^a   Brophy, S ^c   Hyland, J M P ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c NONE

Author keywords

Crohn's disease; Infliximab; Perianal fistulas

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BIOCHEMICAL MARKER; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; PARACETAMOL; STEROID;

ABDOMINAL PAIN; ANESTHESIOLOGICAL TECHNIQUES; ANUS FISTULA; ARTHRALGIA; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG COST; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DYSPNEA; FATIGUE; FEVER; HEADACHE; HEART FAILURE; HISTOPLASMOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION SITE REACTION; LISTERIOSIS; LYMPHOMA; MAINTENANCE THERAPY; MEDICAL LITERATURE; MEDLINE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PATIENT SELECTION; PERIANAL ABSCESS; PHYSICAL EXAMINATION; PNEUMOCYSTOSIS; PNEUMONIA; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUTURING METHOD; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT PLANNING; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 6444234563     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(04)80094-5     Document Type: Review

References (58)

1. Present D, Rutgeerts P, Targan S, Hanauer S, Mayer L, Van Hogezand R, Podolsky D, Sands B, Braakman T, DeWoody K, Schaible T, Van Deventer S. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
2. Arnott I, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001; 15: 1639-46.
3. Cohen R, Tsang J, Hanauer S. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469-77.
4. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997; 92: 559-66.
5. Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kuhn R, Muller W, Berg DJ, Rennick DM. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996; 184:241-51.
6. Kosiewicz MM, Nast CC, Krishnan A, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Kozaiwa K, Cominelli F. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001; 107:695-702.
7. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159:6276-82.
8. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M,Pizarro T, Kotlyarov A, Forster I, Flavell R, Gaestel M, Tsichlis P, Cominelli F, Kollias G. Genetic dissection of the cellular pathways and signaling mechanisms in modeled turnor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002; 196:1563-74.
9. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
10. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J, Daddona PE. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995; 7:15-25.
11. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J, Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7:251-59.
12. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NW, Zinmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-94.
13. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206-11.
14. Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment. Eur J Gastroenterol Hepatol 2004; 16:649-55.
15. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79: 357-65.
16. Parks AG, Gordon PH, Hardcastle JD.A classification of fistula-in-ano. Br J Surg 1976; 63: 1-12.
17. Spencer JA, Chapple K, Wilson D, Ward J, Windsor AC, Ambrose NS. Outcome after surgery for perianal fistula: predictive value of MR imaging. AJR Am J Roentgenol 1998; 171: 403-6.
18. Maruyama R, Noguchi T, Takano M, Takagi K, Morita N, Kikuchi R, Uchida Y. Usefulness of magnetic resonance imaging for diagnosing deep anorectal abscesses. Dis Colon Rectum 2000; 43 (suppl): S2-S5.
19. Ricart E, Panaccione R, Loftus E, Tremaine W, Sandborn W. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-29.
20. Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D'Hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P. MRI imaging of the effects of infliximab in perianal fistulizing Crohn's disease. Am J Gastroenterol 2003; 98: 332-29.
21. Van Bodegraven A, Sloots C, Felt-Bersma R, Meuwissen S. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002; 45: 39-46.
22. Topstad D, Panaccione R, Heine J, Johnson D, MacLean A, Buie W. Combined Seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rates in fistulising anorectal Crohn's disease. Dis Colon Rectum 2003; 46: 577-83.
23. Sandborn W, Hanauer S. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97: 2962-72.
24. Reguiero M, Mardini H. Treatment of perianal fistulising Crohn's disease with infliximab alone or as an adjunct to exam under anaesthesia with Seton placement. Inflammatory Bowel Disease 2003; 9(2): 98-103.
25. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 2002 17: S176-S185.
26. Sands B, Van Deventer S, Bernstein C. Long-term treatment of fistulising Crohn's disease: response to infliximab in the ACCENT 2 trial through 54 weeks. Gastroenterology 2002; 122: A81 (Abstract).
27. Rutgeerts P, Mayer L, Schreiber S, Bao W, Bala M, Keenan G, Olson A, Hanauer S. Infliximab maintenance treatment strategy is superior to episodic treatment in patients with Crohn's disease. Am J Gastroenterol 2002; 96 (Suppl): S302-S303.
28. Present DH, Burton I, Korelitz MD, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-Mercaptopurine. N Engl J Med 1980; 302: 981-87.
29. Farrell R, Shah S, Lodhavia P, Alsahli M, Falchuk K, Michetti P, Peppercorn M. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95: 3490-97.
30. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin THJ. Infliximab User Group. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid sparing immunosuppressive therapy? Int Med J 2001; 31: 146-150.
31. Ochsenkuhn T, Goke B, Sackman M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002; 97: 2022-25.
32. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short -term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
33. Arnott I, McNeill G, Satsangi J. An analysis of factors influencing short term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-57.
34. Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Laskner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-13.
35. Vermiere S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P. Demographic and clinical parameters influencing the short-term outcome of anti-tumour necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-63.
36. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, Fuentes D, Dieguez A, Deschamps E, Perex-Pariente J, Lopez-Vazquez A, de Francisco R, Rodrigo L. High serum tumour necrosis factor alpha levels are associated with lack of response to infliximab in fistulising Crohn's disease. Am J Gastroenterol 2002; 97: 2350-56.
37. Esters N, Vermiere S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P. Serological markers for prediction of response to anti tumour necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 1458-62.
38. Mascheretti S, Hampe J, Kuhbacher T, Herfarth H, Krawczak M, Folsch U, Schreiber S. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. The Pharmacogenomics Journal 2002; 2 127-36.
39. Remicade ™ (Infliximab) Prescribing Information. Centocor, Inc., Malvern, PA, 1998.
40. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large centre experience. Am J Gastroenterol 2003; 98: 1315-24.
41. Farrell R, Alsahli M, Jeen Y, Falchuk K, Peppercorn M, Michetti P. Intravenous hydrocortisone pre-medication reduces antibodies to infliximab in Crohn's disease: a randomised controlled trial. Gastroenterology 2003; 124: 917-24.
42. Hanauer S, Rutgeerts P, D'Haens G, Targan S, Kam L, Present D, Mayer L, Wagner C, LaSorda J, Sands B, Livingston R. Delayed hypersensitivity to infliximab (Remicade) re-infusion after 2-4 year interval without treatment. Gastroenterology 1999; 116: A731 (Abstract).
43. Vermiere S, Noman M, van Assche G, Baert F, van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti-tumour necrosis factor-α treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32-39.
44. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13 Suppl 4: 16-22.
45. Keane J, Gershon S, Wise R, Mirabile-Levens E, Kasznica J, Schwieterman W, Siegel J, Miles Braun M. Tuberculosis associated with infliximab, a tumour necrosis factor alpha neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
46. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Lori Brown S, Udall JN, Miles Braun M. Life-threatening histoplasmosis complicating immunotherapy with tumour necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565-70.
47. Chung E, Packer M, Hung Lo K, Fasanmade A, Willerson J. Randomised, double -blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumour necrosis factor-α, in patients with moderate to severe heart failure. Circulation 2003; 107: 3133-40.
48. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumour necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
49. Ekbom A, Helmick C, Zack M, Adami H. Extra-colonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 2015-19.
50. Bernstein CN, Lanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001; 91: 854-62.
51. Lori Brown S, Greene M, Gershon S, Edwards E, Miles Braun M. Tumour necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum 2002; 46: 3151-58.
52. Robinson W, Genovese M, Moreland L. Demyelinating and neurologic events reported in association with tumour necrosis factor alpha antagonism: by what mechanism could tumour necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44: 1977-83.
53. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992(a); 14: 318-27.
54. Hay AR, Hay JW. Inflammatory bowel disease: costs of illness. J Clin Gastroenterol 1992(b); 14: 309-17.
55. Cohen R, Larson L, Roth J. Becker R, Mummert L. The cost of hospitalisation in Crohn's disease. Am J Gastroenterol 2000; 95 524-30.
56. Rubenstein J, Chong R, Cohen R. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002; 35(2): 151-56.
57. Poritz L, Rowe W, Koltun W. Remicade does not abolish the need for surgery in fistulising Crohn's disease. Dis Colon Rectum 2002; 45: 771-75.
58. Arseneau K, Cohn S, Cominelli F, Connors A. Cost-Utility of initial medical management for Crohn's disease. Gastroenterology 2001; 120: 1640-56.